Bridgeway Capital Management’s Protara Therapeutics TARA Stock Holding History
Bought
Maintained
Sold
Other funds holding TARA
BBA
ACA
Bridgeway Capital Management's TARA Position: Q3 2026 in Review
Bridgeway Capital Management reduced its Protara Therapeutics (TARA) stake by 18% in Q3 2026, selling an estimated $60.4K and leaving 69,830 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #1004.
Bridgeway Capital Management first reported a position in TARA in Q2 2015 and has held it in 30 quarters since. The position peaked at $779K in Q3 2021. 114 funds tracked by Wall St. Rank hold TARA as of Q3 2026.
- Bridgeway Capital Management held 69,830 shares of Protara Therapeutics worth $213K as of Q3 2026.
- Bridgeway Capital Management sold 15,500 Protara Therapeutics shares in Q3 2026, an estimated $60.4K.
- Protara Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1004 holding.
- Bridgeway Capital Management first reported a position in Protara Therapeutics in Q2 2015 and has held it in 30 quarters since.
- Bridgeway Capital Management's Protara Therapeutics position peaked at $779K in Q3 2021.
- 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.